U.S. patent number 3,812,264 [Application Number 05/033,989] was granted by the patent office on 1974-05-21 for method of producing a carrier for a scintigraphic preparation and scintigraphic preparations including said carrier.
This patent grant is currently assigned to U.S. Philips Corporation. Invention is credited to Jean-Paul Nouel.
United States Patent |
3,812,264 |
Nouel |
May 21, 1974 |
**Please see images for:
( Certificate of Correction ) ** |
METHOD OF PRODUCING A CARRIER FOR A SCINTIGRAPHIC PREPARATION AND
SCINTIGRAPHIC PREPARATIONS INCLUDING SAID CARRIER
Abstract
Scintigraphic carriers are obtained by sensitizing red blood
corpuscles by means of a stannous chloride solution having a
physiological pH. The carriers are then labelled with radio-active
pertechnetate. The labelling efficiency is appreciably higher than
in the known methods.
Inventors: |
Nouel; Jean-Paul
(Boisguillaume, FR) |
Assignee: |
U.S. Philips Corporation (New
York, NY)
|
Family
ID: |
9033458 |
Appl.
No.: |
05/033,989 |
Filed: |
May 1, 1970 |
Foreign Application Priority Data
Current U.S.
Class: |
424/1.17;
250/303; 250/493.1; 424/650; 534/14; 556/107; 435/317.1 |
Current CPC
Class: |
A61K
51/1203 (20130101); A61K 51/12 (20130101); G01N
33/50 (20130101); A61K 2123/00 (20130101) |
Current International
Class: |
A61K
51/12 (20060101); G01N 33/50 (20060101); A61k
027/04 () |
Field of
Search: |
;424/1,11,101,131,288
;252/31.1R ;23/23B ;250/16T,71.5S |
Other References
morcellet et al., Nuclear Sci. Abstracts, Vol. 24, No. 4, p. 617
No. 6078-Abstract from J. Biol. Med. Nucl: 4, No. 17, 16-18
(May-June 1969). .
Journal de Biologie et de Midicine Nucleare A.T.E.N., Vol. IV, No.
15 pp. 20-24 (1969)..
|
Primary Examiner: Padgett; Benjamin R.
Attorney, Agent or Firm: Spain; Norman N. Trifari; Frank
R.
Claims
1. A method of producing a carrier for a scintigraphic preparation,
said method comprising subjecting red blood corpuscles to the
action of a stannous chloride solution buffered to a physiological
pH in an amount of, from 0.03 to 1.5 mg of stannous chloride per 10
ml of blood, and removing
2. A method of producing a scintigraphic preparation comprising
subjecting red blood corpuscles to the action of a stannous
chloride solution buffered to a physiological pH, in an amount of
from 0.03 mg to 1.5 mg of stannous chloride per 100 ml of blood,
removing any excess of stannous ions and then treating said red
blood corpuscles with a pertechnetate
4. A carrier for a scintigraphic preparation obtained by the method
of
5. A scintigraphic preparation obtained by the method of claim 1.
Description
The invention relates to a method of producing a carrier for a
scintigraphic preparation in which red blood corpuscles are
sensitized by treatment with a stannous chloride solution. The
invention also relates to a method of producing a scintigraphic
preparation in which tin-sensitized red blood corpuscles are
labelled with radioactive pertechnetate.
From Journal de Biologie et de Medicine Nucleaires A.T.E.N., vol.
IV, no. 15, pages 20-24 (1969) it is known to produce a carrier for
a scintigraphic preparation and to produce a scintigraphic
preparation using this carrier by mixing blood with a 1 percent
heparine solution and then centrifuging. The red blood corpuscles
are subsequently suspensed in a medium consisting of a
physiological salt solution, plasma gel and stannous chloride. The
sensitized red blood corpuscles then are isolated according to
known methods by centrifuging, after which they are brought into
contact with radio-active pertechnetate. After a contact time of 30
minutes, they are again centrifuged and washed four times with a
physiological salt solution. After resuspending in a physiological
salt solution the preparation is ready for use. The labelling
efficiency is 30 percent.
The invention provides a carrier by means of which scintigraphic
preparations are obtainable in which the labelling efficiency is 90
percent. Obviously this is an important practical and economic
improvement: the volume of the scintigraphic preparation to be
administered to a patient can be reduced to one third; the losses
of radio-active material have been reduced to one seventh.
The said improved efficiency is achieved by sensitizing the red
blood corpuscles by means of a stannous chloride solution buffered
to a physiological pH (about 7.4).
The invention thus relates to a method of producing a carrier for a
scintigraphic preparation in which red blood corpuscles are
sensitized by treatment with a stannous chloride solution
characterized in that a stannous chloride solution is used that is
buffered to a physiological pH.
The invention also relates to a method of producing a scintigraphic
preparation in which red blood corpuscles are sensitized by means
of a stannous chloride solution and then labelled with radio-active
pertechnetate, which method is characterized in that for the
sensitizing operation a stannous chloride solution buffered to a
physiological pH is used.
As buffers any physiologically acceptable buffers may be used, such
as alkali citrates, alkali tartrates, alkali phosphates, and the
like.
Sensitization is effected by stirring a suspension of red blood
corpuscles in a buffered stannous chloride solution for a short
time, for example one or a few minutes. The excess of stannous ions
is then removed. This may be performed by centrifuging the
suspension and stirring the sediment in a washing liquid, which
then is again centrifuged. The washing liquid may be a
physiological salt solution. The excess of stannous ions may,
however, be removed more effectively by adding a complex binder,
for example ethylene diamine tetra-acetic acid disodium salt
(EDTA), either to the original suspension or to the washing
liquid.
The amount of stannous chloride required for sensitization may vary
within comparatively wide limits without appreciably influencing
the labelling efficiency. As a rule, from 0.03 to 1.5 mg of
SnCl.sub.2 per 10 ml of blood is used.
Within a period of 9 days after the preparation of the carrier, the
red blood corpuscles may be radio-actively labelled, for example by
means of pertechnetate, without the labelling efficiency being
affected. Labelling may be performed, for example, by a method as
described in French Pat. 1,518,139.
The carrier may be packaged in bottles or injection syringes by
conventional techniques. The radio-active labelling is preferably
effected immediately prior to the use of the preparation.
The scintigraphic preparation can be used for blood tests,
examination of the spleen, the heart, the brain, the blood vessels,
and the like.
EXAMPLE
a. 10 g of stannous chloride was dissolved in 1 ml of 10 N
hydrochloric acid. The solution was added drop by drop to a
solution of 2.715 g of trisodium citrate in 30 ml of distilled
water. The volume was increased to 100 ml with distilled water,
after which sodium hydroxide (about 3.5 ml) was added until the pH
of the solution was 7.4.
1 ml of the resulting solution was added to 10 ml of venous blood.
The mixture was stirred for 1 minute, after which 1 ml of a 5
percent ethylene diamine tetraacetic acid disodium salt solution
was added. After stirring again for 1 minute the liquid was
centrifuged.
The sediment was taken up in 10 ml of a physiological salt
solution, stirred and again sedimentated by centrifuging. Finally
the sediment was again taken up in a physiological salt
solution.
b. The preparation obtained by the method described in a) was
radio-actively labelled with sodium pertechnetate by stirring it
together with 1 ml of a pertechnetate solution taken from the
radio-active milker for 20 minutes. The mixture was centrifuged and
the sediment resuspended in 10 ml of a physiological salt solution,
which treatment was repeated thrice.
The ready product has an activity of 700 .mu.C.
It should be noted that the entire processing was effected under
aseptic conditions.
* * * * *